XIENCE Sierra: Setting the standard for safety
XIENCE: Most Studied, Most Implanted Stent in the World
You Can't Beat Zero: XIENCE Stent Thrombosis Data
One of the key factors in safety with stents is stent thrombosis. XIENCE consistently results in zero stent thrombosis. This best-in-class safety is demonstrated in several clinical trials with real-world patient populations, including complex patients and patients who have discontinued dual antiplatelet therapy (DAPT).
XIENCE: Most Studied Stent in Patients With Reduced Dual Antiplatelet Therapy (DAPT)
DAPT duration often depends on the patient — and it may depend on the stent as well.
Notably, the XIENCE everolimus-eluting stent (EES) has been associated with the lowest rates of early, late and very late stent thrombosis (ST).8-11 Therefore researchers have examined safety outcomes with a reduced DAPT duration following XIENCE implantation.3
AP2945979-WBU Rev. B